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significance (14), although, as has repeatedly been demon-
strated for other phenotypes, this can in part be overcome 
for at least a proportion of risk variants as larger samples 
become available for performing meta-analyses. For GWAS 
of childhood-onset psychiatric disorders, such as ADHD 
and autism, the types of sample sizes required, even with 
international collaboration, have yet to be achieved (15). 
Another possibility is that if ADHD is genetically heteroge-
neous (in the sense that there are multiple phenotypes with 
limited or no overlap at the level of common risk alleles), 
the effects of each allele might be diluted, resulting in lower 
apparent effect sizes. However, it is currently unclear how 
best to subdivide ADHD in a way that might overcome this 
problem or whether such subdivisions are possible.
An alternative explanation for the negative GWAS find-
ings might be that ADHD risk is entirely explained by mul-
tiple low-frequency variants that are not well captured by 
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O b je c t iv e :  A  major motivation for seek-
ing disease-associated genetic variation is 
to identify novel risk processes. Although 
rare copy number variants (CNVs) appear 
to contribute to attention deficit hyperac-
tivity disorder (ADHD), common risk vari-
ants (single-nucleotide polymorphism s 
[SNPs]) have not yet been detected using 
genome-wide association studies (GWAS). 
This raises the concern as to whether fu-
ture larger-scale, adequately powered 
GWAS w ill be worthwhile. The authors un-
dertook a GWAS of ADHD and exam ined 
whether associated SNPs, including those 
below  conventional levels of significance, 
influenced the same biological pathways 
affected by CNVs.
M e tho d :  The authors analyzed genome-
wide SNP frequencies in 727 children 
w ith ADHD and 5,081 comparison sub-
jects. The gene sets that were enriched in 
a pathway analysis of the GWAS data (the 
top 5%  of SNPs) were tested for an excess 
of genes spanned by large, rare CNVs in 
the children w ith ADHD.
R e su lts :  No SNP achieved genome-wide 
significance levels. As previously reported 
in a subsample of the present study, large, 
rare CNVs were significantly more com -
mon in case subjects than comparison 
subjects. Thirteen biological pathways 
enriched for SNP association significantly 
overlapped w ith those enriched for rare 
CNVs. These included cholesterol-related 
and CNS development pathways. At the 
level of individual genes, CHRNA7 , which 
encodes a nicotinic receptor subunit pre-
viously implicated in neuropsychiatric 
disorders, was affected by six large dupli-
cations in case subjects (none in compari-
son subjects), and SNPs in the gene had a 
gene-w ide p value of 0.0002 for associa-
tion in the GWAS.
Co n c lu s io n s :  Both common and rare 
genetic variants appear to be relevant to 
ADHD and index-shared biological path-
ways.
Attention deficit hyperactivity disorder (ADHD) is 
a highly heritable disorder (heritability estimates range 
from 75% to 90% [1, 2]). Rare genetic variants, specifically 
large, rare copy number variants (CNVs), play an impor-
tant role in ADHD (3–5), but so far, genome-wide searches 
have not identified common risk variants. Four published 
genome-wide association studies (GWAS) of ADHD (6–9) 
and a recent meta-analysis (10) of all available data have 
failed to yield genome-wide significant results for any sin-
gle-nucleotide polymorphism (SNP).
There are several explanations as to why it has been dif-
ficult to identify common genetic risk variants for psychiat-
ric disorders (11), including ADHD (12). One important fac-
tor is that the effect size of any individual SNP is likely to be 
small (13). This means that with currently available sample 
sizes, true common risk alleles are unlikely to achieve the 
stringent statistical thresholds required for genome-wide 
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disorders. However, the potential loss of power that is attained by 
using unscreened comparison subjects is more than offset by the 
large numbers of comparison samples available (21).
SNP data for our 100 most strongly associated SNPs were re-
quested from deCODE Genetics and the ADHD GWAS Consor-
tium. The deCODE sample included 1,142 Icelandic individuals 
who met DSM-IV criteria for ADHD. Patients were recruited from 
outpatient psychiatric clinics in Iceland. Diagnoses were based 
on standardized diagnostic assessments and were reviewed by ex-
perienced clinicians as previously described (22). A total of 35,243 
Icelandic individuals were available as comparison subjects (22). 
The second sample consisted of 2,064 parent-child trios, 896 case 
subjects, and 2,455 comparison subjects from the ADHD GWAS 
Consortium meta-analysis and has been described in detail else-
where (10). This data set consists of four projects: the Children’s 
Hospital of Philadelphia, phase I and phase II of the International 
Multisite ADHD Genetics Project, and a Pfizer-funded study from 
the University of California, Los Angeles, Washington University, 
and Massachusetts General Hospital.
Geno typ ing
DNA samples for our ADHD case subjects were genotyped on 
the Illumina (San Diego) Human660W-Quad BeadChip accord-
ing to the manufacturer’s instructions. Comparison subjects were 
genotyped by Wellcome Trust Case Control Consortium–Phase2 
using the Illumina Human 1.2M BeadChip. BeadStudio (version 
2.0) was used to call genotypes and inspect cluster plots. Analysis 
was based on 518,511 SNPs that were present on both chips.
Qua lity  Con tro l A sse ssm en t
Sample and SNP quality control assessments were performed 
using PLINK, version 1.07 (23). Sample quality control assessment 
was performed separately for case and comparison subjects. Full 
details are provided in the data supplement that accompanies the 
online edition of this article. In brief, case and comparison sub-
jects were excluded if there was a call rate less than 0.99, low or 
high heterozygosity, evidence of relatedness, duplication, or non-
European ancestry. Exclusions included one member of related 
pairs. Also, SNPs were excluded if they had a call rate less than 
0.99, had a minor allele frequency less than 0.01, deviated from 
Hardy-Weinberg equilibrium at p<1×10–5, or had more than 1% 
discordant genotypes between the Illumina 550K and the Illu-
mina Human 1.2M BeadChip arrays. After all the quality control, 
502,702 SNPs were tested for association in 727 case subjects and 
5,081 comparison subjects.
CNV  Da ta
The ADHD sample is an extension of 366 cases previously ex-
amined for large, rare CNVs (5). All quality control and CNV de-
the genotyping arrays. In reality, population genetics the-
ory predicts that risk is most likely conferred by alleles that 
span the spectrum of frequencies (13). If it is the case that 
both common and rare variants contribute to ADHD risk, 
but genome-wide significant association cannot be a real-
istic goal with currently sized samples, we might expect to 
see a convergence of subthreshold signals from both types 
of variants influencing common biological risk pathways.
In the present study, we investigated whether specific 
biological pathways were enriched for associated SNPs 
and for CNVs, and whether these overlapped.
M ethod
Sub je c ts  and  C lin ica l M ea su re s
The ADHD patient sample consisted of 799 Caucasian children 
from Cardiff, Wales (N=559); St. Andrews, Scotland (N=44); and 
Dublin, Ireland (N=196). All children were recruited from com-
munity clinics and met DSM-IV or ICD-10 criteria for ADHD or 
hyperkinetic disorder. To be comparable with other GWAS, we ex-
cluded children with a major medical or neurological condition 
(including epilepsy), autism, bipolar disorder, or intellectual dis-
ability (IQ <70).
We obtained approval from North West England, Wales, NHS 
Tayside, and Eastern Regional Health Authority research ethics 
committees. Written informed consent from parents and assent 
from children were obtained.
Trained interviewers used the Child and Adolescent Psychiatric 
Assessment—Parent Version (16), a semistructured research diag-
nostic interview, to assess psychiatric diagnoses. Pervasiveness of 
ADHD symptoms (in school) was assessed using the Child Atten-
tion-Deficit Hyperactivity Disorder Teacher Telephone Interview 
(17) or the Conners Teacher Questionnaire (18). IQ was assessed 
using the WISC-IV (19).
The children were between 4 and 18 years old (mean=10 years 
3 months [SD=3 years]). The sample consisted of 699 boys (87.4%) 
and 100 girls (12.6%). Table 1 summarizes ADHD subtypes and 
comorbidities.
Genotype control data were obtained from the Wellcome Trust 
Case Control Consortium–Phase 2 (20). They comprised 3,000 
individuals born in the United Kingdom during 1 week in 1958 
(the 1958 British Birth Cohort) and 3,000 individuals from the 
U.K. Blood Services collection. It has previously been shown that 
it is valid to combine these two samples for use as comparison 
subjects in genetic association studies using U.K. case samples 
(20). The comparison subjects were not screened for psychiatric 
tA BlE  1 . A DHD  Sub type s and  Com o rb id  D iso rde r r a te s in  7 9 9  Ch ild ren  W ith  A DHD a
Diagnosis N %
ADHD diagnoses (lifetime)a
 DSM-IV ADHD, combined type 498 64.8
 DSM-IV ADHD, predominantly inattentive type 162 21.1
 DSM-IV ADHD, predominantly hyperactive-impulsive type 62 8.1
 DSM-III-R ADHD 46 6.0
Other diagnoses (current)
 DSM-IV conduct disorder 107 13.7
 DSM-IV oppositional defiant disorder 364 46.5
 DSM-IV anxiety disorder (generalized anxiety disorder, separation 
anxiety, or social phobia) 37 4.7
 DSM-IV depressive disorder (any) 22 2.8
a Because data on DSM subtypes for some case subjects are missing, the total is <799.
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Simes test (27), a more powerful and less conservative version of 
the Bonferroni method, which tests SNPs one at a time. The other 
was Fisher’s method for combining p values, which aggregates the 
evidence for all SNPs simultaneously. Since odds ratios must be in 
the same direction as our GWAS to count as replication, one-sided 
p values were used in the analysis. Enrichment was tested in the 
ADHD genetics consortium and deCODE samples separately, and 
in both data sets combined (see the online data supplement). A 
meta-analysis of all three samples (Cardiff ADHD GWAS, ADHD 
genetics consortium, and deCODE) was also performed on each 
of the top 100 SNPs (without pruning) separately.
P a thw ay  ana ly s is  o f C a rd if f GWA S  d a ta . Gene sets used for 
pathway analyses of our GWAS data came from four sources (28): 
Gene Ontology (29), the Kyoto Encyclopedia of Genes and Ge-
nomes (ftp://ftp.genome.jp/pub/kegg/genes/organisms/hsa/hsa_ 
pathway.list), the Mouse Genome Informatics database (30), and 
PANTHER (Protein Analysis Through Evolutionary Relationships 
[31]). Gene sets were required to contain between three and 1,000 
genes to be included in the analysis, giving a total of 12,371 gene 
sets. Analysis was carried out using ALIGATOR (28), which con-
verts a list of significant and nominally significant SNPs into a list 
of significant genes and tests this list for enrichment for genes 
within the gene sets, allowing for variable numbers of SNPs per 
gene. ALIGATOR generates p values for enrichment for each gene 
set and corrects these for testing multiple nonindependent gene 
sets. It also tests whether the number of significantly enriched 
gene sets is higher than expected given the observed set of SNP 
p values in the GWAS. Gene sets required at least two signals 
to be tested to remove the possibility of a small gene set being 
deemed significantly enriched based on one signal. An important 
modification to the original ALIGATOR method is that significant 
genes in the same gene set that are less than 1 Mb apart (and thus 
could be explained by the same association signal) were counted 
as a single signal. SNPs within the boundaries of a gene (genome 
build 36.3) were assigned to that gene: if SNPs mapped to more 
tection protocols were identical to those previously described. 
BeadStudio was used to determine the log R ratio and B allele 
frequency at each SNP according to standard Illumina protocols. 
CNVs were defined by PennCNV (24) with loci spanning at least 
15 consecutive informative SNPs, with those having copy num-
ber calls <2 and >2 being classed as deletions and duplications, 
respectively. Samples with a high standard deviation in their 
genome-wide log R ratio (>0.30) and carrying more than 30 ap-
parent CNVs over 100 kb were also excluded. Large (classified as 
those >500 kb) and rare (<1% frequency) CNVs were used in this 
analysis because they are called with greater accuracy, have bet-
ter concordance across different platforms, and show the most 
robust associations with neurodevelopmental disorders (5).
Sta tistica l A na ly sis
GWA S . SNPs were tested for association with ADHD using logis-
tic regression in PLINK assuming an additive model. The EIGEN-
STRAT software package was used to calculate principle com-
ponents by inferring continuous variation in allele frequencies 
reflecting ancestral differences in individuals (25). Two principle 
components were identified and used to control for population 
stratification since they had the maximum impact on the ge-
nomic control inflation factor l. Genome-wide significance was 
considered to be achieved when the p value reached 5×10–8 (26).
Genotype data for the top 100 SNPs from the present GWAS 
were requested from the ADHD genetics consortium (10) and de-
CODE. In these samples, we tested for enrichment of association 
of our top 100 SNPs after linkage disequilibrium pruning (see the 
online data supplement). There were 204 samples from the pres-
ent GWAS that overlapped with those included in the ADHD ge-
netics consortium GWAS meta-analysis. Overlap was statistically 
accounted for in the analysis (see the online data supplement). 
There was no overlap between those two data sets and that of 
deCODE. Two methods were used to test for enrichment of associ-
ation signal in the combined set of SNPs. The first of these was the 
tA BlE  2 . top  2 0  independen t S ing le -Nuc leo tid e  Po lym o rph ism s (SNP s) in  an  A DHD  G enom e -W ide  A sso c ia tion  S tudy  (GWA S )
Minor Allele
SNP
Chromo-
some Position Closest Gene
Location Relative 
to Gene
Minor 
Allele
Other 
Allele
Minor Allele 
Frequency p
Odds 
Ratio 95% CI
rs1744062 6 137350879 IL20RA Within noncoding 
gene
G A 0.43 4.16E-06 0.75 0.67–0.85
rs11079828 17 43964102 HOXB1 Upstream T C 0.47 6.54E-06 1.32 1.17–1.49
rs42259 5 14439655 TRIO Intronic T C 0.17 6.76E-06 1.41 1.22–1.64
rs3779312 7 77549692 MAGI2 Intronic T C 0.21 8.38E-06 1.37 1.19–1.57
rs616668 12 110458663 ATXN2 Intronic G T 0.20 8.62E-06 1.38 1.20–1.59
rs11175219 12 62648986 SRGAP1 Intronic T C 0.12 1.06E-05 1.46 1.23–1.73
rs4238186 13 18588836 LOC100128765 Intergenic A G 0.18 1.11E-05 1.39 1.20–1.61
rs7746680 6 45885325 - Intergenic A G 0.24 1.14E-05 1.35 1.18–1.54
rs11686538 2 225526808 DOCK10 Intronic G A 0.29 1.27E-05 0.74 0.64–0.84
rs1304358 2 198677828 PLCL1 Intronic C T 0.49 1.27E-05 1.30 1.16–1.47
rs406742 10 8885947 - Intergenic G A 0.26 1.49E-05 1.33 1.17–1.51
rs790531 13 49623515 DLEU2 Within noncoding 
gene
G A 0.06 1.50E-05 1.62 1.30–2.02
rs6815704 4 93693589 GRID2 Intronic A G 0.15 2.09E-05 1.40 1.20–1.64
rs9842394 3 181095930 PEX5L Intronic T C 0.47 2.68E-05 0.77 0.69–0.87
rs2636788 10 98866931 SLIT1 Intronic G A 0.17 2.74E-05 0.70 0.59–0.83
rs1490046 5 173888653 - Intergenic A G 0.08 2.87E-05 1.56 1.27–1.92
rs1050567 2 61559167 XPO1 3′ untranslated 
region
T C 0.11 2.89E-05 1.44 1.22–1.72
rs9384245 6 155201820 TIAM2 Intronic T C 0.42 3.00E-05 0.77 0.68–0.87
rs1370072 13 54739939 - Intergenic T C 0.45 3.28E-05 1.29 1.14–1.45
rs874836 22 15681843 XKR3 Intronic A G 0.13 3.32E-05 1.41 1.20–1.67
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meta-analysis data set (Simes p=0.176, Fisher’s p=0.159) 
or in deCODE (Simes p=0.291, Fisher’s p=0.621), or when 
both data sets (all published reports) were meta-analyzed 
(Simes p=0.135, Fisher’s p=0.095). The individual p values 
for each of the 60 independent SNPs from these analyses 
are listed in Table S2 in the online data supplement. The 
individual p values for the top 100 Cardiff SNPs (see Table 
S1 in the online data supplement) and the p values from 
meta-analysis of the Cardiff ADHD GWAS, ADHD Genet-
ics Consortium meta-analysis, and deCODE data sets are 
listed in Table S3 in the online data supplement. In the 
combined analysis of all data, no marker SNPs approached 
genome-wide significance (pmin=6.38×10–6 at rs11698703).
Pa thw ay  A na ly sis  o f  Ca rd iff  SNP  Da ta
In the ALIGATOR analysis of our GWAS data set, 315 
pathways were enriched at p<0.05 and 81 at p<0.01. More 
categories were enriched at the more stringent threshold 
(p=0.033) given the distribution of p values in the genes in 
the data set as a whole, but none was significant after cor-
recting for multiple testing. Enrichment p values for the 
top 100 significant pathways are listed in Table S4 in the 
online data supplement.
Ove rlap  o f  En riched  Pa thw ays B e tw een  CNV  and  
SNP  Da ta
We included 727 ADHD case subjects and 1,047 compar-
ison subjects in the CNV analysis. We observed a signifi-
cantly (p=0.002) higher rate of large (>500 kb), rare CNVs in 
case subjects (N=85, 21 deletions, 64 duplications) than in 
comparison subjects (N=78, 13 deletions, 65 duplications). 
In the subset of the 727 ADHD case subjects (N=409) that 
had not been included in the previous report (5), the rate 
than one gene, they were assigned to all such genes. Using this 
method, 203,663 SNPs were assigned to 14,929 genes. As before 
(32), the significant genes included the top 5% of all genes repre-
sented by SNPs, which was a total of 746 genes with at least one 
SNP (p<0.0054).
o ve r lap  o f GWA S  and  CNV  p a thw ay s . Gene sets with nomi-
nally significant (p<0.05) enrichment in the pathway analysis 
of the GWAS data were tested for an excess of genes affected by 
large, rare CNVs in case subjects by fitting the following logistic 
model, which overcomes biases relating to gene and CNV size 
(33), to the combined set of CNVs:
logit (pr[case]) = CNV size + total number of annotated genes af-
fected outside the gene set + number of genes affected in the gene set
and comparing the change in deviance between it and the 
model 
logit (pr[case]) = CNV size + total number of annotated genes 
affected outside the gene set.
The comparison of case to control CNVs allows for the possibil-
ity of nonrandom CNV location unrelated to disease (i.e., CNVs 
tend to occur in specific locations of the genome, and this is un-
related to case status). A one-sided test for an excess of genes af-
fected by case CNVs was performed. The inclusion of CNV size in 
the regression allows for case CNVs being of different size than 
typical CNVs (and thus likely to affect more genes, regardless of 
function). Inclusion of the total number of genes affected outside 
the gene set in the regression corrects for case CNVs affecting 
more genes overall (regardless of function) than control CNVs. 
Analysis was restricted to gene sets containing at least eight gene 
hits in total (case and control combined), since pathways with a 
large number of gene hits are more likely to be biologically mean-
ingful. This criterion is different from that used for the ALIGATOR 
analysis of GWAS data (two significant genes) for two reasons. 
First, each gene is counted only once in ALIGATOR but can be 
counted multiple times in the CNV analysis (if hit by multiple 
CNVs). Second, two significant genes may be sufficient to flag 
a pathway of interest in a GWAS context if these gene associa-
tions are sufficiently significant. Correction for multiple testing 
was applied by randomly permuting case/control status of CNVs 
and repeating the analysis 5,000 times. This procedure gave a cor-
rected p value for enrichment of gene hits in case CNVs for each 
gene set as well as a test of whether more gene sets than expected 
are significantly enriched. The latter gives a test of overlap in the 
pathways enriched for rare CNVs and common associated SNPs.
re su lts
GW AS
The quantile-quantile plot of the observed versus ex-
pected chi-square tests is presented in Figure 1. The ge-
nomic control inflation factor l was 1.069. Standardized 
to a sample size of 1,000, l1,000 was 1.054. No SNP achieved 
genome-wide significance. Table 2 lists the top 20 inde-
pendent SNPs ordered by significance.
We next sought replication for our top SNPs (see Table 
S1 in the online data supplement). To obtain 100 inde-
pendent SNPs, we linkage disequilibrium pruned the 
GWAS data set using PLINK. For pairs of SNPs less than 
1 Mb apart with r2>0.2, only the most significant SNP in 
the Cardiff GWAS in each pair was retained, leaving a to-
tal of 60 SNPs. No significant excess signal was observed 
among these SNPs in the ADHD Genetics Consortium 
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D iscu ssion
In a sample of 727 children with ADHD and 5,081 com-
parison subjects, there was no evidence of genome-wide 
significant association with any SNP. In keeping with pre-
vious results from a subsample of the present study, we 
found an increased burden of large and rare CNVs. Analy-
sis of our top 100 SNPs in the ADHD genetics consortium 
meta-analysis and deCODE data sets yielded no signifi-
cant evidence of association, after allowing for testing 
of individual SNPs, when the 100 SNPs were considered 
together and when the discovery GWAS data were com-
bined with those from the other data sets. These results 
add to the four published GWAS studies of ADHD (6–10) 
that include meta-analyses in which no genome-wide sig-
nificant findings had been found. The lack of significant 
GWAS findings could simply reflect sample sizes that are 
inadequate for the multiple testing burden, and it may 
be that when much larger samples are assembled for ex-
tended meta-analyses, common risk variants will be de-
tected. That more sets of genes were significantly enriched 
for subthreshold association signals is consistent with this 
hypothesis, as it implies that the distribution of the asso-
ciation signals with respect to genes is not random.
One major motivation for undertaking genetic studies is 
to identify underlying biological risk mechanisms. In the 
present study, we sought evidence on whether the path-
ways enriched for SNP association converge with those 
enriched for rare CNVs. Our finding of significant evidence 
for such a convergence underscores our contention that 
it is premature to dismiss the contribution of SNP varia-
tion, but more importantly, it begins to provide evidence 
that genome-wide studies of ADHD, based on common or 
rare variants, are likely to inform processes of relevance to 
of large, rare CNVs was also significantly greater than in 
the comparison subjects (rate=0.112, compared with 
0.075; p=0.02). More information is provided in Table S5 in 
the online data supplement.
More of the gene sets that were nominally significantly 
enriched in the ALIGATOR analysis of the SNP data were 
also significantly enriched for case CNVs (Figure 2). Thus, 
of the 315 pathways with enrichment at p<0.05 from the 
SNP data, in the CNV data 13 were enriched at p<0.05, 
eight at p<0.01, and seven at p<0.001. These numbers are 
significantly higher than expected by chance (p=0.0080, 
p=0.0022, p<0.0001, respectively). The 13 pathways sig-
nificantly enriched (p<0.05) in both the SNP data and the 
CNV data are listed in Table 3. Although there was strong 
evidence of SNP and CNV signal convergence at the level 
of pathways, this was not evident at the individual gene 
level. Within the 13 significantly enriched pathways, 63 
genes for which there were gene-wide (Simes) p values 
from the GWAS were affected by at least one CNV in a case 
subject or a comparison subject. Among these, there was 
some correlation (r=0.236) between genes showing evi-
dence for association (−log GWAS Simes p and −log CNV 
enrichment p) at the level of SNPs and CNVs, but this did 
not quite achieve statistical significance (p=0.063).
The exception to this was CHRNA7, which is a member 
of the Gene Ontology (GO) categories “cation channel 
activity” (GO:5261; case CNV hits enrichment p=0.0184, 
GWAS enrichment p=0.042), “channel regulator activ-
ity” (GO:16247; p=0.0307, p=0.026), and “regulation of 
tumor necrosis factor production” (GO:32680; p=0.0088, 
p=0.014). CHRNA7 was affected by six duplications in case 
subjects but none in comparison subjects (p=9.08×10–4) 
and had a Simes-corrected gene-wide p value of 0.0002 
from the GWAS.
tA BlE  3 . Pa thw ay s Show ing  Nom ina lly  S ign ifican t En richm en t (p<0 .0 5 ) in  Bo th  the  S ing le -Nuc leo tid e  Po lym o rph ism  D a ta  
and  the  Copy  Num be r Varian t (CNV ) D a ta  in  a  G enom e -W ide  A sso c ia tion  S tudy  o f  A DHD
Pathway 
Numbera
Number 
of Genes
Gene Hits 
(Cases)
Gene Hits 
(Comparison) p (CNV) p (corr)b p (GWAS) Description
MGI:5278 188 14 0 1.47E-05 0.002 0.030 Abnormal cholesterol homeostasis
MGI:3947 182 13 0 2.61E-05 0.004 0.023 Abnormal cholesterol level
MGI:180 169 13 0 2.61E-05 0.004 0.026 Abnormal circulating cholesterol level
GO:16746 214 14 0 1.42E-04 0.009 0.004 Transferase activity, transferring acyl groups
GO:8415 203 13 0 1.43E-04 0.009 0.003 Acyltransferase activity
GO:16747 205 13 0 1.43E-04 0.008 0.004 Transferase activity, transferring acyl groups 
other than amino-acyl groups
GO:51298 11 8 0 6.95E-04 0.050 0.033 Centrosome duplication
GO:32680 34 7 1 8.83E-03 0.341 0.014 Regulation of tumor necrosis factor production
GO:5261 271 17 6 1.84E-02 0.547 0.042 Cation channel activity
GO:7417 441 28 10 2.77E-02 0.683 0.002 Central nervous system development
GO:16247 56 8 2 3.07E-02 0.719 0.026 Channel regulator activity
GO:8233 572 25 8 4.89E-02 0.848 0.037 Peptidase activity
GO:70011 553 25 8 4.89E-02 0.848 0.038 Peptidase activity, acting on L-amino acid 
peptides
a GO=Gene Ontology; MGI=Mouse Genome Informatics
b Represents the probability of obtaining by chance at least one pathway with a pathway-specific p value for enrichment of case CNV hits at 
least as significant as that observed in the actual data. Note that genes <1 Mb apart in the same pathway were collapsed into one signal.
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CNVs and SNPS. This implies that both types of gene vari-
ants are relevant to ADHD risk. Finally, our results suggest 
that CHRNA7 is a promising candidate to examine further.
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pathophysiology. At present, our study is not sufficiently 
powered to identify any of these categories unambigu-
ously. Significant pathways included those related to cho-
lesterol (four pathways) and CNS development. The latter 
has been previously implicated in ADHD (3), although dif-
ferent methods were used. The lack of a clear overlap at 
the level of individual genes may reflect true differences 
in the specific genes within pathways implicated by SNPs 
and CNVs, perhaps arising from the different mutational 
mechanisms responsible for generating large CNVs and 
SNPs, neither of which occur randomly with respect to the 
genomic sequence context. However, it is also likely that it 
reflects low power to identify specific risk genes. Although 
not supported at a genome-wide level of significance, the 
convergence of SNP and CNV association at CHRNA7, 
which encodes the cholinergic receptor nicotinic alpha 
7, is intriguing. CHRNA7 is widely expressed in the brain, 
especially the hippocampus (34), and is involved in rapid 
synaptic transmission. CHRNA7 has been examined in re-
lation to schizophrenia, associated cognitive deficits, and 
nicotine dependence (35, 36), although findings have not 
been entirely consistent. There has been little published 
work on ADHD, although incomplete evaluations of the 
gene in much smaller samples have not been supportive 
(37). Thus, to date this gene has yet to be comprehensively 
investigated in relation to ADHD.
Small duplications and deletions on 15q13.3 have been 
found to be associated with neuropsychiatric phenotypes 
that include ADHD. Recurrent deletions of chromosome 
15q13.3 are associated with developmental delay and a va-
riety of neuropsychiatric phenotypes. It has been suggest-
ed that haploinsufficiency of CHRNA7 may have a causal 
role (38). Duplications spanning CHRNA7 have also been 
found to be associated with a broad range of neuropsy-
chiatric phenotypes that include ADHD (39, 40). Increased 
dosage of CHRNA7 in these microduplications has been 
considered to be responsible.
GWAS and CNV studies capture only a proportion of 
genetic variation and do not allow for the effects of un-
measured genetic and environmental risk factors. In the 
future, the next generation of sequencing studies will go 
some way toward addressing some of these gaps. The 
pathway analysis using ALIGATOR relies on Gene Ontol-
ogy, the Kyoto Encyclopedia of Genes and Genomes path-
ways, Mouse Genome Informatics, and PANTHER-defined 
functional categories (28). The ability to detect enriched 
pathways will depend on how well and how accurately bi-
ological processes are defined, and again, this knowledge 
will evolve over time.
In summary, in keeping with similarly sized previous ge-
nome-wide association studies of ADHD, we failed to find 
significantly associated common variants. We previously 
found large, rare CNVs to be associated with ADHD, and 
the results remain similar in this newly extended sample. 
Contrary to what some might expect, we found a highly 
significant overlap of biological pathways hit by both 
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